Syros Pharmaceuticals Inc (SYRS)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
0.0250 +0.0009 (+3.73%) 15:52 ET [OTC US]
N/A x N/A N/A x N/A
Post-market - - (-) 15:52 ET
for Tue, Apr 15th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
Cash Flows From Operating Activities | |||||
Net Income | -164,574 | -94,654 | -86,558 | -84,038 | -75,438 |
Depreciation Amortization | 2,826 | 3,398 | 3,724 | 3,322 | 2,722 |
Accounts receivable | N/A | N/A | 7 | 19,993 | -20,158 |
Accounts payable and accrued liabilities | 5,133 | 2,766 | 48 | -1,057 | 1,493 |
Other Working Capital | 5,055 | -5,517 | -10,602 | 12,087 | 3,754 |
Other Operating Activity | 41,853 | -29,058 | -6,159 | -7,671 | 27,374 |
Operating Cash Flow | $-109,707 | $-123,065 | $-99,540 | $-57,364 | $-60,253 |
Cash Flows From Investing Activities | |||||
Change In Deposits | 36,049 | 68,426 | -51,408 | 50,000 | 794 |
PPE Investments | 1,288 | -1,241 | -1,245 | -3,336 | -12,528 |
Investing Cash Flow | $37,337 | $67,185 | $-52,653 | $46,664 | $-11,734 |
Cash Flows From Financing Activities | |||||
Debt Issued | N/A | N/A | N/A | 39,619 | N/A |
Debt Repayment | -65 | -291 | -265 | -241 | -205 |
Common Stock Issued | 43,527 | 119,979 | 70,817 | 103,782 | 61,557 |
Common Stock Repurchased | N/A | -81 | N/A | N/A | N/A |
Other Financing Activity | 0 | 11,438 | -41 | -207 | 4,638 |
Financing Cash Flow | $43,462 | $131,045 | $70,511 | $142,953 | $65,990 |
Beginning Cash Position | 170,553 | 95,388 | 177,070 | 44,817 | 50,814 |
End Cash Position | 141,645 | 170,553 | 95,388 | 177,070 | 44,817 |
Net Cash Flow | $-28,908 | $75,165 | $-81,682 | $132,253 | $-5,997 |
Free Cash Flow | |||||
Operating Cash Flow | -109,707 | -123,065 | -99,540 | -57,364 | -60,253 |
Capital Expenditure | -272 | -1,241 | -1,245 | -3,336 | -12,638 |
Free Cash Flow | -109,979 | -124,306 | -100,785 | -60,700 | -72,891 |